Hybrid Florbetaben PET/MRI Scans to Study Heart Amyloidosis Patients
Studies whether a florbetaben PET/MRI scan predicts heart problems in people with heart amyloidosis.
Plain-language title generated from the registry record
Registry title: Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis
Key facts
- Where
- Essen, GermanySee the site
Where in Germany
- Department of Nuclear medicine, University Hospital EssenEssen, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Essen
- Trial code
- NCT07154381
- Record updated
- 4 September 2025
- Original description
Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).Read full original descriptionShow less
Monocentric Observational Trial for Florbetaben PET/MRI Hybrid Imaging in Patients With Cardiac Amyloidosis
Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).
Inclusion: Age > 40 years; proven Amyloidosis (ATTR or AL); Women: negative pregnancy test less than weeks prior imaging.
Exclusion: Patients receiving amyloidosis-specific treatment prior study inclusion; Contraindiactions for MRI (eGFR<30ml/min/1.73m2; gadolinium allergy; metallic implants or device not suited for 3T MRI); Patients participating in other clinical trails for treatment of Amyloidosis; Pregnancy; inability of consent; Refusal of consent.